제일바이오 Stock: price and insider trades · South Korea

제일바이오 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). 4 insiders have disclosed 6 filings since 10 November 2025.

The record shows 2 purchases on the open market, made by 1 insider, against 4 sales by 3 insiders. The amount is not disclosed for 6 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price.

The most recent open-market purchase was published on 24 February 2026, 259 days ago. The median gap between a trade and its publication by DART (FSS) is 10 days. This delay matters because a trade only becomes useful information once it is public. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

For context, the typical company on the same exchange (median of 2,648 companies) published 7 filings over the same period, against 6 filings here. Looking back to 2021, when coverage begins, insiders filed 16 purchases and 4 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from DART (FSS). Past trades are no guide to future returns.